28186998|t|Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers
28186998|a|A recurrent germline mutation (G84E) in the HOXB13 gene is associated with early onset and family history -positive prostate cancer in patients of European descent, occurring in up to 5% of prostate cancer families. To date, the molecular features of prostate tumors occurring in HOXB13 G84E carriers have not been studied in a large cohort of patients. We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls. Immunostaining for HOXB13, PTEN, ERG, p53 and SPINK1 as well as RNA in situ hybridization for ETV1 / 4 / 5 were performed using genetically validated assays. Tumors from G84E carriers generally expressed HOXB13 protein at a level comparable to benign and wild-type glands. ETS gene expression (either ERG or ETV1 / 4 / 5) was seen in 36% (36/101) of tumors from G84E carriers compared to 68% (65/96) of the controls (p < 0.0001). PTEN was lost in 11% (11/101) of G84E carriers compared to 25% (25/99) of the controls (p = 0.014). PTEN loss was enriched among ERG - positive compared to ERG - negative tumors in both groups of patients. Nuclear accumulation of the p53 protein, indicative of underlying TP53 missense mutations, was uncommon in both groups, occurring in 1% (1/101) of the G84E carriers versus 2% (2/92) of the controls (p = NS). Taken together, these data suggest that genes other than ERG and PTEN may drive carcinogenesis / progression in the majority of men with germline HOXB13 mutations.
28186998	0	7	Somatic	T080	C2986476
28186998	8	27	molecular subtyping	T059	C0022885
28186998	31	46	prostate tumors	T191	C0033578
28186998	52	58	HOXB13	T028	C1415664
28186998	59	72	G84E carriers	T045	C0206530
28186998	85	109	germline mutation (G84E)	T045	C0206530
28186998	117	128	HOXB13 gene	T028	C1415664
28186998	148	159	early onset	T033	C1833334
28186998	164	178	family history	T033	C0241889
28186998	189	204	prostate cancer	T191	C0600139
28186998	208	216	patients	T101	C0030705
28186998	220	236	European descent	T098	C1535514
28186998	263	278	prostate cancer	T191	C0600139
28186998	279	287	families	T099	C0015576
28186998	302	320	molecular features	T085	C0026383
28186998	324	339	prostate tumors	T191	C0033578
28186998	353	359	HOXB13	T028	C1415664
28186998	360	373	G84E carriers	T045	C0206530
28186998	417	425	patients	T101	C0030705
28186998	445	474	heterozygous carriers of G84E	T045	C0206530
28186998	489	510	radical prostatectomy	T061	C0194810
28186998	515	530	prostate cancer	T191	C0600139
28186998	578	582	race	T098	C0034510
28186998	584	587	age	T032	C0001779
28186998	592	603	tumor grade	T191	C0027651
28186998	610	616	HOXB13	T028	C1415664
28186998	617	626	wild-type	T028	C1883559
28186998	627	635	controls	T096	C0009932
28186998	637	651	Immunostaining	T059	C0022885
28186998	656	662	HOXB13	T116,T123	C1436058
28186998	664	668	PTEN	T116,T126	C1430988
28186998	670	673	ERG	T116,T123	C0295291
28186998	675	678	p53	T116,T123	C0080055
28186998	683	689	SPINK1	T116,T123	C1452174
28186998	701	704	RNA	T114	C0035668
28186998	705	726	in situ hybridization	T063	C0162788
28186998	731	735	ETV1	T028	C1333361
28186998	738	739	4	T028	C1333362
28186998	742	743	5	T028	C1414477
28186998	765	793	genetically validated assays	T059	C0005507
28186998	795	801	Tumors	T191	C0027651
28186998	807	820	G84E carriers	T045	C0206530
28186998	831	840	expressed	T045	C1171362
28186998	841	855	HOXB13 protein	T116,T123	C1436058
28186998	892	901	wild-type	T028	C1883559
28186998	910	913	ETS	T028	C0812380
28186998	914	929	gene expression	T045	C0017262
28186998	938	941	ERG	T028	C0599295
28186998	945	949	ETV1	T028	C1333361
28186998	952	953	4	T028	C1333362
28186998	956	957	5	T028	C1414477
28186998	987	993	tumors	T191	C0027651
28186998	999	1012	G84E carriers	T045	C0206530
28186998	1044	1052	controls	T096	C0009932
28186998	1067	1071	PTEN	T116,T126	C1430988
28186998	1076	1080	lost	T169	C0745777
28186998	1100	1113	G84E carriers	T045	C0206530
28186998	1145	1153	controls	T096	C0009932
28186998	1167	1171	PTEN	T116,T126	C1430988
28186998	1172	1176	loss	T081	C1517945
28186998	1196	1199	ERG	T116,T123	C0295291
28186998	1202	1210	positive	T033	C1446409
28186998	1223	1226	ERG	T116,T123	C0295291
28186998	1229	1237	negative	T033	C0205160
28186998	1238	1244	tumors	T191	C0027651
28186998	1253	1259	groups	T096	C0009932
28186998	1263	1271	patients	T101	C0030705
28186998	1273	1293	Nuclear accumulation	UnknownType	C0544910
28186998	1301	1312	p53 protein	T116,T123	C0080055
28186998	1339	1343	TP53	T028	C0079419
28186998	1344	1362	missense mutations	T045	C0599155
28186998	1385	1391	groups	T096	C0009932
28186998	1424	1437	G84E carriers	T045	C0206530
28186998	1462	1470	controls	T096	C0009932
28186998	1503	1507	data	T078	C1511726
28186998	1521	1526	genes	T028	C0017337
28186998	1538	1541	ERG	T028	C0599295
28186998	1546	1550	PTEN	T028	C0694888
28186998	1561	1575	carcinogenesis	T191	C0596263
28186998	1578	1589	progression	T169	C0449258
28186998	1609	1612	men	T098	C0025266
28186998	1618	1643	germline HOXB13 mutations	T045	C0206530